Intezyne Technologies, Incorporated

Tyndall Formulation Services, LLC

The University of Texas System

The University of Arizona

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Bold Therapeutics, Inc.

Calusa Bio, LLC

R-pharm US Operating LLC

Interzyne Technologies, Inc.

Kevin N Sill

Habib Skaff

Kurt Breitenkamp

Adam Carie

Tomas Vojkovsky

Bradford T Sullivan

Rebecca Breitenkamp

Jonathan L Sessler

Victor J Hruby

Robert J Gillies

David L Morse

Josef Vagner

Narges Tafreshi

Christian Preihs

Natalie M Barkey

Gregoire Cardoen

Janni Mirosevich

Jonathan Rios-Doria

Joseph Edward Semple

Hooshmand Sheshbaradaran

Jonathan Rios-Doris

Broadford T Sullivan

Edward J Semple

The present invention relates to the preparation of compositions comprising sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)]. Synthesis and formulation preparation is detailed. Impurity profiles are also discussed. Compositions herein are useful for anti-cancer applications.

Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imagable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Melanocortin 1 receptor ligands and methods of use

The present disclosure relates to the field of polymer chemistry and more particularly to multiblock copolymers comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block and uses thereof.

Polymer excipients for drug delivery applications

This disclosure relates to the field of formulations of SN-38 with a poly(amino acid) copolymer and methods of making and using thereof. Compositions herein are drug products suitable for the treatment of cancer.

Formulations of SN-38 with poly(amino acid) block polymers

The present disclosure relates to the field of polymer chemistry and more particularly to poly(sarcosine) polymers and uses thereof. The disclosure is also directed to compositions comprising a protein and a poly(sarcosine) polymer and uses thereof.

Poly(sarcosine) polymer excipients

Provided herein are compositions comprising ixabepilone, or a pharmaceutically acceptable salt thereof, and a copolymer represented by formula I: Also provided are methods of treating cancer using the compositions described herein, and methods of preparing the compositions.

Compositions of ixabepilone

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

This disclosure relates to the field of formulations of paclitaxel with a poly(amino acid) copolymer and methods of making and using thereof. Compositions herein are drug products suitable for the treatment of cancers.

Formulations of paclitaxel with poly(amino acid) block polymers

The present invention provides SN-38 compositions for treating cancer.

SN-38 loaded iron crosslinked micelle and methods thereof

Growing community of inventors

Tampa, FL, United States of America

Kevin N Sill